Brainomix 360 e-CTA vs Swoop® Portable MR Imaging® System

Tool B (Swoop) appears to have a significant edge in usability due to its portable nature, allowing imaging at the point of care and reducing the need for patient transport. Its iPad-based interface and quick setup time (under two minutes) also contribute to a more user-friendly experience for a broader range of healthcare professionals. Tool A (Brainomix 360 e-CTA) is a software solution that integrates with existing PACS and offers a mobile app, but it still relies on traditional CT angiography scans.

Tool B (Swoop) offers significant clinical value by making MRI accessible at the point of care, which is crucial for critically ill patients who cannot be transported to a conventional MRI. It provides diagnostic-quality images for various brain conditions, including stroke, hemorrhage, and hydrocephalus, and has shown time-saving benefits in emergency settings. While Tool A (Brainomix 360 e-CTA) provides rapid and reliable analysis of CT imaging for acute stroke, its role is as a decision support tool, augmenting expert interpretation rather than providing primary diagnostic imaging.

Both tools require contacting the vendor for specific pricing details, making a direct comparison difficult. Tool B (Swoop) has a reported cost of around $250,000, which is significantly less than conventional MRI machines, and eliminates the need for expensive shielded rooms. Tool A (Brainomix 360 e-CTA) offers flexible licensing options for individual modules or packages, and a health economic analysis found its full stroke platform to be highly cost-effective. Without more transparent pricing for Tool A, it's challenging to definitively declare a winner in terms of overall value.

Tool A (Brainomix 360 e-CTA) is part of the broader Brainomix 360 Stroke platform, which is designed for comprehensive stroke imaging across multiple modalities (NCCT, CTA, CTP, MRI) and includes an enterprise analytics dashboard (Brainomix 360 Vantage) for network-wide insights. It supports integration with all major scanner and PACS manufacturers and offers a mobile app for network-wide access and communication. Tool B (Swoop) is also deployed in over 200 systems globally and is designed for use in various healthcare settings, including hospitals and specialized clinics, with DICOM compatibility for PACS integration. However, Brainomix's comprehensive platform approach and analytics dashboard suggest a more robust enterprise-level solution for managing stroke pathways across an entire network.

Tool B (Swoop) represents a more significant innovation by introducing the world's first FDA-cleared portable MRI system, overcoming major accessibility barriers of traditional MRI. Its ultra-low-field magnetic resonance combined with AI-powered image reconstruction is a novel approach to bringing MRI to the point of care. Tool A (Brainomix 360 e-CTA) offers advanced AI for CT angiography analysis, but it's an enhancement to existing imaging modalities rather than a fundamentally new imaging device.

Both companies appear to offer comprehensive support and documentation. Brainomix provides user manuals, FAQs, and contact options for support. Hyperfine offers 24/7/365 technical support through various channels (UI, web, phone, email), including remote assistance and software upgrades. Both emphasize ongoing support and updates, making it difficult to distinguish a clear winner without direct user feedback on the quality and responsiveness of their support services.